Predicting a pipeline

Compugen Ltd. has spent more than a decade developing and refining its in silico prediction platform to discover novel peptides and proteins that can be developed as therapeutics or targets. The company has neither the resources nor the desire to move into the clinic, but it has found potential partners are looking for more than proof of concept in an initial disease model.

Thus, last year, Compugen began selecting candidates to move forward into lead optimization and other preclinical activities intended to support pre-IND development. The hope is that an additional 12-18 months of work on candidates focused on hot targets in cancer and immunology will result in higher-value deals...